Loading
Life sciences · Journal article
Current Cancer Therapy Reviews · October 12, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract: Cancer genomics has transformed the field of oncology, with cancer now considered a highly heterogeneous and genetically complex disease driven by a variety of somatic and germline alterations. This complexity, which includes mutations in oncogenes and tumor suppressor genes, often undermines conventional therapies and leads to drug resistance and relapse, underscoring the critical need for precision medicine. CRISPR-Cas9 system is a revolutionary gene-editing technology that can overcome these challenges by allowing for precise, efficient, and programmable genome modification. Here, the study reviews the different applications of CRISPR-Cas9 in cancer research and therapy. It highlights its foundational role in creating advanced in vitro and in vivo cancer models, enabling the accurate reproduction of tumor biology and the performance of mechanistic studies. Also discussed is the utility of CRISPR-based functional genomic screens to identify novel therapeutic targets and resistance mechanisms. Therapeutically, CRISPR-Cas9 provides promising strategies such as direct gene modification for oncogene inactivation, tumor suppressor restoration, and reversal of multidrug resistance. The most advanced clinical application of it is in immunotherapy, especially the engineering of improved CAR-T cells and other immune effectors. In addition, CRISPR-targeted tumor microenvironment and oncogenic virus offer new strategies for cancer treatment. The problems of off-target effects, delivery challenges, and ethical concerns are serious obstacles despite its enormous potential. Progress in delivery systems and genome-editing precision, as well as in clinical trials, continues to advance CRISPR-Cas9 to become part of routine oncology practice, and to drive forward the paradigm of personalized cancer therapy.